Bill · H.R. 6321· House(119-HR-6321)
Lung Cancer Medicare Access to Precise Testing Act
- Introduced
- 11/28/2025
- Last activity
- 11/28/2025 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Josh Gottheimer
- Cosponsors
- - 2 - 1
- Introduced
- In Committee
What this bill would do
This bill, known as the "Lung Cancer Medicare Access to Precise Testing Act," seeks to change the Social Security Act. It would require the Medicare program to cover lung cancer biomarker testing. This type of testing involves analyzing an individual's tissue, blood, or bodily fluids to identify specific biomarkers like genes or proteins. The coverage would apply to individuals diagnosed with lung cancer for tests furnished on or after January 1, 2027. Additionally, the bill mandates that Medicare pay 100 percent of the reasonable charges for this specific testing.
Yes· 3 of 5
Would people over 65 be better off under this?+8
The bill provides full Medicare coverage for lung cancer biomarker testing, which benefits many seniors undergoing cancer treatment.
Would retired people be better off under this?+8
The bill ensures that retirees on Medicare have access to full coverage for critical lung cancer biomarker testing.
Does this make health care easier to get in general?+8
The bill mandates Medicare coverage for essential lung cancer biomarker testing, facilitating easier access to precise diagnostics.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Medicare Coverage for Lung Cancer Testing: The bill amends the Social Security Act to include lung cancer biomarker testing as a covered service under Section 1861(s)(2). This allows individuals diagnosed with lung cancer to have specific biomarkers, such as genes or proteins, identified through the analysis of their tissue, blood, or bodily fluids (Section 2(a)).
-
Full Payment for Testing: Under Section 2(b), the bill amends Section 1833(a)(1) of the Social Security Act to ensure that the amount paid for lung cancer biomarker testing is 100 percent of the reasonable charges. This means Medicare would cover the full reasonable cost of these tests for eligible individuals.
Potential Negative Impacts for People
- No specific negative impacts are mentioned in the provided text: The text focuses entirely on the requirements for coverage and payment levels without listing any negative consequences or burdens.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Retirees+8Good For Seniors+8Good For Low Income Households+5
- Healthcare
- Improves Healthcare Access+8Increases Medicare Funding+7
- 2/3/2026
- 1 Cosponsor added.
- 12/15/2025
- 1 Cosponsor added.
- 11/28/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
Adelita GrijalvaDemocrat · Arizona
Jennifer KiggansRepublican · Virginia
Eric SwalwellDemocrat · California